Charles River Laboratories International Inc Revenue Growth Rates (CRL), Current and Historic Growth - CSIMarket
CSIMarket
 


Charles River Laboratories International inc   (NYSE: CRL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

CRL's Revenue Growth by Quarter and Year

Charles River Laboratories International Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CRL/growth
https://api.csimarket.com/api/v1/companies/CRL/fundamentals
https://api.csimarket.com/api/v1/companies/CRL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
CRL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 982.73
2nd Quarter June 1,004.08
1st Quarter March 995.83
FY 2,982.64

CRLs Annual Revenue
Charles River Laboratories International Inc 's Revenue in the fiscal year 2025 $ 4,015.38 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2024 $ 4,049.99 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2023 $ 4,129.41 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2022 $ 3,976.06 millions
Charles River Laboratories International Inc 's Revenue in the fiscal year 2021 $ 3,540.16 millions




CRL Revenue third quarter 2026 Y/Y Growth Comment
Charles River Laboratories International Inc reported decrease in Revenue in the third quarter 2026 by -2.2% to $ 982.73 millions, from the same quarter in 2025.
The decrease in the third quarter 2026 Charles River Laboratories International Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 8.13%.

Looking into third quarter 2026 results within Medical Laboratories industry 26 other companies have achieved higher Revenue growth. While Charles River Laboratories International Inc ' s Revenue decline of -2.2% ranks overall at the positon no. 3050 in the third quarter 2026.




CRL Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -2.2 %
2nd Quarter June -2.72 %
1st Quarter March 1.18 %
FY   -

Financial Statements
Charles River Laboratories International Inc 's third quarter 2026 Revenue $ 982.73 millions CRL's Income Statement
Charles River Laboratories International Inc 's third quarter 2025 Revenue $ 1,004.85 millions Quarterly CRL's Income Statement


CRL Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -2.13 %
2nd Quarter June 0.83 %
1st Quarter March 0.16 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #27
Healthcare Sector #419
Overall #3050

Revenue Y/Y Growth Statistics
High Average Low
33.99 % 8.13 % -8.94 %
(Apr 01 2017)   (Sep 28 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #27
Healthcare Sector #419
Overall #3050
Revenue Y/Y Growth Statistics
High Average Low
33.99 % 8.13 % -8.94 %
(Apr 01 2017)   (Sep 28 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Charles River Laboratories International Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
22.31 % 1.96 % -6.41 %
(Jun 25 2016)  


CRL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Charles River Laboratories International Inc disclosed fall in Revenue from the second quarter by -2.13% to $ 982.73 millions, from $ 1,004.08 millions achived in the previous reporting period.

But that's not important problem, as Charles River Laboratories International Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Charles River Laboratories International Inc 's Revenue growth quarter on quarter, overall rank is 1631.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #220
Overall #1631
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #12
Healthcare Sector #220
Overall #1631
Revenue Q/Q Growth Statistics
High Average Low
22.31 % 1.96 % -6.41 %
(Jun 25 2016)  


CRL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Charles River Laboratories International Inc disclosed fall in Revenue from the second quarter by -2.13% to $ 982.73 millions, from $ 1,004.08 millions achived in the previous reporting period.

But that's not important problem, as Charles River Laboratories International Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Laboratories industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Charles River Laboratories International Inc 's Revenue growth quarter on quarter, overall rank is 1631.


Charles River Laboratories International Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 27 2026)
12 Months Ending (Mar 28 2026) 12 Months Ending (Dec 27 2025) 12 Months Ending (Sep 27 2025) 12 Months Ending (Jun 28 2025)
Cumulative Revenue 12 Months Ending $ 3,998.99
Y / Y Revenue Growth (TTM) -0.74 %
Year on Year Revenue Growth Overall Ranking # 2691
Seqeuential Revenue Change (TTM) -0.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 2575


Cumulative Revenue growth Comment
For the 12 months ended Jun 27 2026 Charles River Laboratories International Inc reported a decrease in Revenue by -0.74% year on year, to $3,999 millions, compare to the 0.11% growth at Mar 28 2026.

In the Healthcare sector 384 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2263 to 2691.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 24
Healthcare Sector # 385
Overall # 2691

Revenue TTM Y/Y Growth Statistics
High Average Low
26.8 %
11.37 %
-3.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 373
S&P 500 # 2575
Cumulative Revenue growth Comment
For the 12 months ended Jun 27 2026 Charles River Laboratories International Inc reported a decrease in Revenue by -0.74% year on year, to $3,999 millions, compare to the 0.11% growth at Mar 28 2026.

In the Healthcare sector 384 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2263 to 2691.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 24
Healthcare Sector # 385
Overall # 2691

Revenue TTM Y/Y Growth Statistics
High Average Low
26.8 %
11.37 %
-3.67 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 24
Sector # 373
S&P 500 # 2575




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CRL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decrease for the quarter ending Sep 26 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 26 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Charles River Laboratories International Inc Revenue Growth Rates (CRL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Charles River Laboratories International Inc (CIK 1100682).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001100682-26-000157
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Charles River Laboratories International Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.